Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoni Ribas

Showing results (41-50 of 467) with videos related to

Pageof 47
Sort By:
Cancer Immunology Research|January 8, 2026
The Next Chapter of Cancer Immunology ResearchElizabeth M Jaffee, Antoni Ribas
The Journal of Experimental Medicine|December 2, 2016
What does PD-L1 positive or negative mean?Antoni Ribas, Siwen Hu-Lieskovan
Cancer Discovery|May 3, 2020
Trying for a BRAF Slam DunkAntoni Ribas, Roger S Lo
Cancer Cell|June 14, 2017
SnapShot: Immune Checkpoint InhibitorsGabriel Abril-Rodriguez, Antoni Ribas
Cancer Immunology Research|January 16, 2021
At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for CancerMarina Chiara Garassino, Antoni Ribas
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 3, 2021
Leadership Focus on Advancing Cancer Research and Treatment: A Conversation Between Johannes Czernin, Caius Radu, and Antoni RibasJohannes Czernin, Caius Radu, Antoni Ribas
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it?John Glaspy, Antoni Ribas, Bartosz Chmielowski
Cancer Treatment and Research|November 26, 2015
Targeted Therapy for MelanomaDeborah J L Wong, Antoni Ribas
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2013
Reply to K.S. Wilson et alAntoni Ribas, Axel Hauschild, Richard Kefford
Seminars in Immunology|February 11, 2016
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?Lidia Robert, Antoni Ribas, Siwen Hu-Lieskovan
Pageof 47

Showing results (41-50 of 467) with videos related to

Sort By:
Pageof 47
Cancer Immunology Research|January 8, 2026
The Next Chapter of Cancer Immunology ResearchElizabeth M Jaffee, Antoni Ribas
The Journal of Experimental Medicine|December 2, 2016
What does PD-L1 positive or negative mean?Antoni Ribas, Siwen Hu-Lieskovan
Cancer Discovery|May 3, 2020
Trying for a BRAF Slam DunkAntoni Ribas, Roger S Lo
Cancer Cell|June 14, 2017
SnapShot: Immune Checkpoint InhibitorsGabriel Abril-Rodriguez, Antoni Ribas
Cancer Immunology Research|January 16, 2021
At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for CancerMarina Chiara Garassino, Antoni Ribas
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 3, 2021
Leadership Focus on Advancing Cancer Research and Treatment: A Conversation Between Johannes Czernin, Caius Radu, and Antoni RibasJohannes Czernin, Caius Radu, Antoni Ribas
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it?John Glaspy, Antoni Ribas, Bartosz Chmielowski
Cancer Treatment and Research|November 26, 2015
Targeted Therapy for MelanomaDeborah J L Wong, Antoni Ribas
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2013
Reply to K.S. Wilson et alAntoni Ribas, Axel Hauschild, Richard Kefford
Seminars in Immunology|February 11, 2016
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?Lidia Robert, Antoni Ribas, Siwen Hu-Lieskovan
Pageof 47